Robert Lisicki - 03 Jan 2022 Form 4 Insider Report for ARENA PHARMACEUTICALS INC

Reporting relationship: EVP, Chief Commercial Officer
Issuer ticker: N/A
Reported as of: 03 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2022, 16:00:19 UTC
Prior SEC filing: 05 Aug 2021
Next SEC filing: 11 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Andrew J. Cronauer, as Attorney-in-Fact

Key filing fact

Robert Lisicki filed Form 4 for ARENA PHARMACEUTICALS INC on 05 Jan 2022.

Key facts

This page summarizes Robert Lisicki's Form 4 filing for ARENA PHARMACEUTICALS INC.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jan 2022, 16:00.

Change

Previous filing in this sequence was filed on 05 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARNA transaction

Common Stock

Award

Transaction value: $0
Shares: +21,462
Change %: +133%
Price: $0.000000
Shares after: 37,563
Date: 03 Jan 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on February 15, 2023, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of May, August, November, and February. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units.